HTG Molecular Diagnostics, Inc. and the Icahn School of Medicine at Mount Sinai announced they have entered into a new research collaboration as part of HTG?s Transcriptome Panel Early Adopter Program. HTG will provide in-kind laboratory services utilizing its proprietary HTG EdgeSeq technology in connection with multiple Icahn Mount Sinai bladder cancer studies. Launched in August 2021, HTG?s Transcriptome Panel, is designed to measure approximately 20,000 mRNA targets using the HTG EdgeSeq technology. HTG?s panel reduces sample input requirements, is less sensitive to sample age, provides for faster turnaround times than other currently available methods and has a higher sample success rate than RNA-Seq for gene expression profiling. The collaboration between HTG and Icahn Mount Sinai involves three separate clinical study cohorts focused on bladder cancer. The first project includes approximately 160 non-muscle-invasive bladder samples from cancer patients treated at hospitals across Sweden and were part of the ?25-year-follow-up of the 1995-1996 Stockholm bladder cancer? project. Utilizing the HTG Transcriptome Panel, Icahn Mount Sinai will examine treatment-na?ve samples for transcriptional signatures that could be used to potentially predict treatment outcomes and long-term survival. The second project includes muscle-invasive bladder cancer (MIBC) samples from patients treated with immune checkpoint blockade immunotherapies at hospitals across the United States. From this study, pre-treatment trans-urethral resections of bladder tumors (TURBTs) from 108 patients (54 complete responders and 54 non-responders) will be assessed with the HTG Transcriptome Panel, with the goal of identifying transcriptional signatures that may predict treatment response or treatment failure. The third project includes MIBC samples from patients treated with chemotherapy (gemcitabine and cisplatin) along with PD-1 blockade as a potential bladder-sparing approach. Data from the HTG Transcriptome Panel of TURBTs from 68 patients (34 complete responders and 34 non-responders) will be evaluated with the goal of identifying transcriptional signatures that may predict treatment response or treatment failure as part of a bladder sparing treatment protocol.